Celnova Pharma -

Enter your search

NEWS

Celnova Pharma Selected by Alnylam Pharmaceuticals for Exclusive Distribution Agreement in Colombia for GIVLAARI® (givosiran), the First-in-Class RNAi Therapeutic for the Treatment of Acute Hepatic Porphyria (AHP)

− GIVLAARI is the First Therapy Proven to Prevent AHP Attacks – Bogota, Colombia, November 18th, 2020 – Celnova Pharma, a Latin American company focused in complex therapeutic areas, announced today that the company has entered into an exclusive distribution agreement with Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) for GIVLAARI® (givosiran), a first-in-class RNAi therapeutic for the treatment […]

Celnova Pharma Selected by Alnylam Pharmaceuticals for Exclusive Distribution Agreement in Argentina for ONPATTRO® (patisiran), the First-in-Class RNAi Therapeutic

Buenos Aires, Argentina, 4 November 2020 – Celnova Pharma, a Latin American company focused in complex therapeutic areas, today announced the company has entered into an exclusive distribution agreement with Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, for ONPATTRO®, a first-in-class RNAi therapeutic for the treatment of hATTR amyloidosis in adults with Stage 1 […]

CELNOVA PHARMA ANNOUNCES DISTRIBUTION AGREEMENT FOR APOKINON®

Celnova Pharma today announced that it has entered into an exclusive distribution agreement with Laboratoire Aguettant of France to commercialize APOKINON® (apomorphine self-injection pen) in the Argentine market. APOKINON® will be part of Celnova Pharma’s growing Central Nervous System portfolio. Under the new agreement, Celnova Pharma will be responsible for marketing authorizations, market access, commercialization […]

Celnova announces distribution agreement with Norgine

Celnova announces distribution agreement with Norgine

Celnova Pharma today announced that it has entered into an exclusive distribution agreement with SpePharm AG, a wholly owned subsidiary of Netherlands-based Norgine B.V., to commercialize DANTROLEN™ (dantrolene sodium) in the Argentine market. Under the new agreement, Celnova Pharma will be responsible for marketing authorizations, market access, commercialization and distribution in Argentina. “We are excited […]